Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SequestOx
- Development stage
- Unknown
- Lead developer
- Elite Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**SequestOx** is an investigational, immediate-release oral fixed-dose combination of oxycodone hydrochloride and sequestered naltrexone hydrochloride developed by Elite Pharmaceuticals for management of moderate to severe acute pain when an opioid analgesic is appropriate. Intact capsules are designed to release oxycodone for analgesia while retaining naltrexone within the formulation. If the capsule beads are crushed, chewed, or dissolved, naltrexone is released to antagonize opioid receptors and reduce the euphoric effects sought through tampering. Its NDA received an FDA Complete Response Letter in July 2016; Elite subsequently conducted reformulation and bioequivalence work, but reported in its fiscal-year 2026 filing that branded-product development was paused.
- Brand names
- SequestOx
- Other names
- oxycodone + naltrexoneoxycodone + sequestered naltrexoneoxycodone hydrochloride + naltrexone hydrochloride
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on SequestOx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SequestOx.